2. Academic Validation
  3. Verbena Attenuates Adriamycin-Induced Renal Tubular Injury via Inhibition of ROS-ERK1/2-NLRP3 Signal Pathway

Verbena Attenuates Adriamycin-Induced Renal Tubular Injury via Inhibition of ROS-ERK1/2-NLRP3 Signal Pathway

  • Evid Based Complement Alternat Med. 2022 Sep 28;2022:7760945. doi: 10.1155/2022/7760945.
Yicen Zhou 1,  Qijing Wu 2,  Zhenfang Du 1,  Min Huang 1,  Kun Gao 3,  Xiaowei Ma 1,  Hui Zhang 1,  Sheng Qiang 1,  Wei Sun 3
Affiliations

Affiliations

  • 1 Department of Nephropathy, Center Laboratory, Zhangjiagang Traditional Chinese Medicine Hospital, Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang 215600, Jiangsu, China.
  • 2 Department of Traditional Chinese Medicine, Huai'an First People's Hospital, Nanjing Medical University, Huai'an 223399, Jiangsu, China.
  • 3 Division of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210004, Jiangsu, China.
PMID: 36212965 DOI: 10.1155/2022/7760945
Abstract

Chronic kidney disease (CKD) has become a global public health problem. Tubular epithelial cell injury plays a vital role in the progression and prognosis of CKD. Therapies to protect tubular cells is the key to delaying CKD progression. Our study found that verbena, a natural traditional Chinese herb, has a potential reno-protective role in kidney diseases. However, the detailed mechanism remains unknown. In the current study, we employed adriamycin (ADR)-induced renal tubular cell injury to mimic the conditions of tubular injury in vitro. Results showed that total aqueous exact of verbena (TAEV) ameliorated ADR-induced cell disruption, loss of cellular viability, and Apoptosis via inhibition of ROS-ERK1/2-mediated activation of NLRP3 signal pathway, suggesting that TAEV serves as a promising renoprotective agent in delaying the progression of CKD, while ROS-ERK1/2-mediated NLRP3 signal pathway might be a novel target in treating kidney diseases.

Figures
Products